Palvella Therapeutics (PVLA) Capital Expenditures (2014 - 2023)
Palvella Therapeutics (PVLA) reported Capital Expenditures of -$184000.0 for Q4 2023, down 118.22% year-over-year from $1.0 million in Q4 2022, and down 267.27% on a QoQ basis from $110000.0 in Q3 2023.
Palvella Therapeutics (PVLA) has 10 years of Capital Expenditures data on file, last reported at -$184000.0 in Q4 2023.
- Quarterly Capital Expenditures fell 118.22% year-over-year to -$184000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$184000.0 (down 115.41% YoY) and the FY2022 annual result came in at $1.0 million, up 9.69% from the prior year.
- Capital Expenditures slipped to -$184000.0 in Q4 2023 per PVLA's latest filing, from $110000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.9 million in Q1 2020 and bottomed at -$840000.0 in Q3 2020.
- The 5-year median for Capital Expenditures is $175000.0 (2019), against an average of $358900.0.
- Peak annual rise in Capital Expenditures reached 1492.56% in 2020, while the deepest fall reached 462.07% in 2020.
- Tracing PVLA's Capital Expenditures over 5 years: stood at $1.2 million in 2019, then slumped by 50.85% to $578000.0 in 2020, then soared by 64.19% to $949000.0 in 2021, then rose by 6.43% to $1.0 million in 2022, then tumbled by 118.22% to -$184000.0 in 2023.
- Per Business Quant, the three latest PVLA Capital Expenditures figures stand at -$184000.0 (Q4 2023), $110000.0 (Q3 2023), and $26000.0 (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -184,000.00 |
| Dec 31, 2023 | -184,000.00 |
| Sep 30, 2023 | 110,000.00 |
| Sep 30, 2023 | 110,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | 48,000.00 |
| Mar 31, 2023 | 48,000.00 |
| Dec 31, 2022 | 1.01 Mn |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 16,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | -283,000.00 |
| Jun 30, 2022 | -283,000.00 |
| Mar 31, 2022 | 298,000.00 |
| Mar 31, 2022 | 298,000.00 |
| Dec 31, 2021 | 949,000.00 |
| Dec 31, 2021 | 949,000.00 |
| Sep 30, 2021 | -257,000.00 |
| Sep 30, 2021 | -257,000.00 |
| Jun 30, 2021 | 229,000.00 |
| Jun 30, 2021 | 229,000.00 |
| Mar 31, 2021 | 28,000.00 |
| Mar 31, 2021 | 28,000.00 |
| Dec 31, 2020 | 578,000.00 |
| Dec 31, 2020 | 578,000.00 |
| Sep 30, 2020 | -840,000.00 |
| Sep 30, 2020 | -840,000.00 |
| Jun 30, 2020 | 1.06 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.93 Mn |
| Mar 31, 2020 | 1.93 Mn |
| Dec 31, 2019 | 1.18 Mn |
| Dec 31, 2019 | 1.18 Mn |
| Sep 30, 2019 | 232,000.00 |
| Sep 30, 2019 | 232,000.00 |
| Jun 30, 2019 | 933,000.00 |
| Jun 30, 2019 | 933,000.00 |
| Mar 31, 2019 | 121,000.00 |
| Mar 31, 2019 | 121,000.00 |
| Dec 31, 2018 | 565,000.00 |
| Dec 31, 2018 | 565,000.00 |
| Sep 30, 2018 | 325,000.00 |
| Sep 30, 2018 | 325,000.00 |
| Jun 30, 2018 | 394,000.00 |
| Jun 30, 2018 | 394,000.00 |
| Mar 31, 2018 | 414,000.00 |
| Mar 31, 2018 | 414,000.00 |
| Dec 31, 2017 | 819,000.00 |
| Dec 31, 2017 | 819,000.00 |
| Sep 30, 2017 | 289,000.00 |
| Sep 30, 2017 | 289,000.00 |
| Jun 30, 2017 | 663,000.00 |
| Jun 30, 2017 | 663,000.00 |
| Mar 31, 2017 | 179,000.00 |
| Mar 31, 2017 | 179,000.00 |
| Dec 31, 2016 | 237,294.00 |
| Dec 31, 2016 | 237,294.00 |
| Sep 30, 2016 | 198,098.00 |
| Sep 30, 2016 | 198,098.00 |
| Jun 30, 2016 | 56,689.00 |
| Jun 30, 2016 | 56,689.00 |
| Mar 31, 2016 | 67,919.00 |
| Mar 31, 2016 | 67,919.00 |
| Dec 31, 2015 | 351,482.00 |
| Dec 31, 2015 | 351,482.00 |
| Sep 30, 2015 | 194,979.00 |
| Sep 30, 2015 | 194,979.00 |
| Jun 30, 2015 | 33,638.00 |
| Jun 30, 2015 | 33,638.00 |
| Mar 31, 2015 | 40,648.00 |
| Mar 31, 2015 | 40,648.00 |
| Jun 30, 2014 | 4,961.00 |
| Jun 30, 2014 | 4,961.00 |
| Mar 31, 2014 | 1,768.00 |
| Mar 31, 2014 | 1,768.00 |